scholarly journals Survival outcomes in elderly Taiwanese women according to breast cancer subtype and lymph node status: A single-center retrospective study

PLoS ONE ◽  
2021 ◽  
Vol 16 (12) ◽  
pp. e0261258
Author(s):  
Kung-Hung Lin ◽  
Huan-Ming Hsu ◽  
Kuo-Feng Hsu ◽  
Chi-Hong Chu ◽  
Zhi-Jie Hong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Breast Cancer Subtype ◽  
Lymph Node Status ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Luminal B ◽  
Node Status ◽  
Taiwanese Women ◽  
Cancer Subtype

This study aimed to determine the rates of overall survival and recurrence-free survival among elderly Taiwanese women (>65 years old) according to breast cancer subtype and lymph node status. We identified 554 eligible patients who were >65 years old and had been treated based on international recommendations at our center between June 2005 and June 2015. Patients with the luminal A subtype had the highest rates of overall survival (90.6%) and recurrence-free survival (97.0%), while the lowest overall survival rate was observed in those with the triple-negative subtype (81.3%) and the lowest recurrence-free survival rate was observed in those with the luminal B subtype (84.0%). Multivariate Cox proportional hazard analysis, using the luminal A subtype as the reference, revealed significant differences in recurrence-free survival among luminal B patients according to lymph node status. Among elderly Taiwanese women with breast cancer, the breast cancer subtype might help predict survival outcomes. The luminal B subtype was associated with poor recurrence-free survival, and lymph node status was useful for predicting recurrence-free survival in this subset of patients.

Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy

2016 ◽  
Vol 161 (1) ◽  
pp. 173-179 ◽  
Author(s):  
Lior Z. Braunstein ◽  
Alphonse G. Taghian ◽  
Andrzej Niemierko ◽  
Laura Salama ◽  
Alexander Capuco ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Local Recurrence ◽  
Breast Cancer Subtype ◽  
Breast Conserving Therapy ◽  
Lymph Node Status ◽  
Node Status ◽  
Cancer Subtype

Expression of CXCR4 is associated with axillary lymph node status in patients with early breast cancer

The Breast ◽  
2006 ◽  
Vol 15 (4) ◽  
pp. 533-539 ◽  
Author(s):  
Y.-C. Su ◽  
M.-T. Wu ◽  
C.-J. Huang ◽  
M.-F. Hou ◽  
S.-F. Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Early Breast Cancer ◽  
Axillary Lymph Node ◽  
Lymph Node Status ◽  
Axillary Lymph ◽  
Axillary Lymph Node Status ◽  
Node Status

Comparison of Survival Outcomes for Axillary Surgery Extent Based on Intraoperative Sentinel Lymph Node Biopsy Result After Neoadjuvant Chemotherapy for Breast Cancer

2021 ◽  
Author(s):  
Jung Whan Chun ◽  
Jisun Kim ◽  
Il Yong Chung ◽  
Beom Seok Ko ◽  
Hee Jeong Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Neoadjuvant Chemotherapy ◽  
Axillary Recurrence ◽  
Recurrence Free Survival ◽  
Free Survival ◽  
Axillary Surgery ◽  
Distant Metastasis Free Survival

Abstract PurposeTo investigate the survival difference between limited axillary surgery and full axillary lymph node dissection (ALND) in patients with 1-3 positive sentinel lymph node biopsies (SLNBs) after neoadjuvant chemotherapy (NAC).MethodWe retrospectively analyzed data from 676 patients who underwent surgery between 2007 and 2017 with cT1-4, cN0-3, cM0 breast cancer at the time of diagnosis and 1-3 positive SLNBs after NAC. The patients received either SLNB only or completed level I or II ALND based on SLNB results. After propensity score matching, 483 patients who had undergone SLNB only (n=188) and ALND (n=295) were included. We examined overall survival, axillary recurrence-free survival, regional recurrence-free survival, and distant metastasis-free survival and compared them between the subgroups.ResultAt a median follow-up of 59.4 months, no significant statistical difference was observed in overall survival, axillary recurrence-free survival, regional recurrence-free survival, and distant metastasis-free survival between SLNB only and ALND. No significant differences were observed in the 5-year axillary recurrence-free survival (93.1% vs. 94.0%, hazard ratio [HR]=0.94, 95% confidence interval [CI]=0.43-2.05, p=0.876) and 5-year overall survival (97.7% vs. 97.3%, HR=1.65, 95% CI=0.58-4.65, p=0.347) between the two groups.ConclusionOur analysis suggests that SLNB alone may be a possible option for patients with 1-3 sentinel node-positive breast cancer following NAC without significant compromise of recurrence or overall survival.

Immunohistochemical Profiles of Breast Cancer Patients at MRCCC Siloam Semanggi Hospital in 2018

2021 ◽  
Vol 11 (5) ◽  
pp. 392-400
Author(s):  
Fajar Lamhot Gultom ◽  
Marliana Nurprilinda ◽  
Ryani Nur Cahyaning Hutami
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Subtype ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Proliferation Markers ◽  
Luminal B ◽  
Cancer Subtype ◽  
Anatomy Laboratory ◽  
Grade Ii ◽  
Her 2

Immunohistochemistry examination (IHC) is one of the additional tests to diagnose and determine breast cancer subtype. IHC examination is a method to check intracellular protein using a monoclonal and polyclonal antibody to detect the antigen in tissue. IHC examination determined by hormone receptor markers (ER and PR), HER-2/Neu expression, and apoptotic and proliferation markers (Ki-67 and p53) can be used to determine therapy and prognosis. This study aims to determine the hormonal status of breast cancer patient at Siloam Semanggi Hospital in 2018, in the form of age, gender, pathology diagnose, and the result of IHC (ER, PR, HER2, and Ki-67). This study is a retrospective descriptive study using pathological anatomy laboratory results of breast cancer in MRCCC Siloam Semanggi Hospital and 208 patients following inclusion and exclusion criteria. The result obtained is that the age group with the highest frequency is 50-59 years, with 34.1%. The highest frequency by gender is a woman with 99.5%. Carcinoma mammae NST with grade II and III was found in 38.0% of patients. The hormonal receptor with ER and PR positive was found in 51.0% of patients. HER2 expression negative was found in 56.7% of patients. High proliferation Ki-67 was found in 82.7% of patients. Luminal B with HER2 negative subtype was found in 32.2% of patients. Patients in 50-59 years with Luminal B with HER2 negative subtype was found in 26 patients. Patients in carcinoma mammae NST with grade II with Luminal B with HER2 negative subtype was found in 27 patients. Keywords: Breast cancer, pathologic anatomy, immunohistochemistry, breast cancer subtype

Correlation of Histologic Grade and Lymph Node Status with Some Histopathologic Discriminants in Breast Cancer

1986 ◽  
Vol 72 (1) ◽  
pp. 43-51 ◽  
Author(s):  
Mariano Urdiales-Viedma ◽  
Francisco Nogales-Fernandez ◽  
Sebastian Martos-Padilla ◽  
Emilio Sanchez-Cantalejo
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Histologic Grade ◽  
Lymph Node Status ◽  
Node Status
Sign in / Sign up

Export Citation Format

Share Document